Cryptophycin Conjugates With Linker Functionalization for Plasma Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cryptophycin-based antibody-drug conjugates face stability issues in murine plasma, synthesis challenges, and limited efficacy against solid tumors, necessitating the development of novel, potent cytotoxins with improved targeting capabilities.
Innovation Solution
Development of new cryptophycin compounds and conjugates with specific functionalization in unit D or C of the cryptophycin structure, allowing attachment of targeting moieties via linkers, enhancing stability and cytotoxicity, and incorporating diverse linker and spacer units for targeted tumor therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cryptophycin-based antibody-drug conjugates are developed for cancer therapy, then cytotoxicity against cancer cells is improved, but stability in murine plasma deteriorates
Solution Approach 1:
The cryptophycin molecule is divided into distinct functional units (units A-D) with specific functionalization at units C or D, allowing independent optimization of cytotoxicity and stability properties through selective modification of specific segments while maintaining the core macrocycle structure
Solution Approach 2:
Specific functional groups are introduced at localized positions (units C or D) of the cryptophycin structure to attach targeting moieties and linkers, creating local modifications that enhance plasma stability without compromising the overall cytotoxic mechanism of the molecule
2Reliability
If cryptophycin compounds are functionalized for targeted therapy, then efficacy against solid tumors is improved, but synthesis complexity increases
Solution Approach 1:
The patent establishes predetermined functionalization patterns at specific units (C or D) of the cryptophycin structure, with pre-defined reactive groups and linker attachment points that streamline subsequent conjugation steps and reduce synthesis complexity for targeted therapy development
Solution Approach 2:
The functional groups introduced at units C or D are designed to serve multiple purposes: enabling attachment of various targeting moieties, providing linker connection points, and maintaining cytotoxic activity, thereby reducing the need for separate specialized modifications for different therapeutic applications
Data Source
AI summary
The present invention relates to cryptophycin compounds, to new cryptophycin payloads, to new cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents.